Clinical trial

Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)

NCT02033941

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2018-07-03

PhasePHASE2

Study timeline

Study start (actual)2018-07-03Date precision: day

Registry last updated2024-10-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Alzheimer's Diseaseunresolved

Interventions

Meganatural-Az Grapeseed ExtractDRUG

PlaceboDRUG

Sponsors & collaborators

Hillel Grossmanlead sponsor

National Center for Complementary and Integrative Health (NCCIH)collaborator

Mapped research locations

New YorkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02033941 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.